The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Lebanon Plan Commission on Monday night unanimously approved a design plan for Eli Lilly and Co.’s $4.5 billion center for advanced manufacturing and drug development at the LEAP Research and ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

A sign for Eli Lilly & Co. appears outside their corporate headquarters ... Additional approvals like that and Lilly’s push ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been making waves in the biopharmaceutical industry with its strong portfolio of ...